Beigene, ltd. (BGNE)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15
Current assets:
Cash and cash equivalents

1,957

618

856

918

764

712

643

438

490

239

208

261

97

87

85

58

208

17

Short-term restricted cash

0

0

14

14

14

14

14

31

17

0

-

-

-

-

-

-

-

-

Short-term investments

1,417

364

375

618

849

1,068

1,390

931

973

597

548

146

229

280

118

168

38

82

Accounts receivable, net

65

70

55

58

58

41

37

33

23

29

10

-

-

-

-

-

-

-

Unbilled receivable

-

-

0

0

6

-

4

12

23

0

170

-

-

-

-

-

-

-

Inventories

28

28

37

49

13

16

19

6

7

10

5

-

-

-

-

-

-

-

Prepaid expenses and other current assets

126

90

95

96

89

90

69

63

49

35

17

11

8

6

6

6

4

5

Total current assets

3,595

1,172

1,435

1,755

1,796

1,943

2,180

1,516

1,585

913

962

418

336

374

209

232

251

106

Long-term restricted cash

2

2

30

9

8

13

52

-

-

0

-

-

-

-

-

-

-

-

Property, plant and equipment, net

240

242

226

212

197

157

111

90

76

62

55

33

30

25

16

9

7

6

Intangible assets, net

5

5

6

6

6

7

7

6

7

7

7

-

-

-

-

-

-

-

Land use right, net

91

82

75

74

72

45

11

12

12

12

12

-

-

-

-

-

-

-

Goodwill

-

-

0

0

0

-

0

0

0

0

1

-

-

-

-

-

-

-

Deferred tax assets

37

37

42

31

30

29

16

16

11

7

7

4

2

0

-

-

-

-

Other non-current assets

94

68

64

60

58

53

28

11

14

42

2

16

6

4

8

8

5

3

Total non-current assets

472

439

445

394

375

305

228

137

123

132

86

55

40

31

25

18

13

10

Total assets

4,067

1,612

1,881

2,150

2,172

2,249

2,408

1,653

1,708

1,046

1,049

473

376

405

235

251

265

116

Liabilities and shareholders' equity
Current liabilities:
Accounts payable

98

122

112

148

105

113

85

85

52

69

35

24

20

11

7

6

3

8

Accrued expenses and other payables

179

163

133

103

90

100

75

75

55

49

46

22

24

22

21

14

11

8

Advances from customers

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

Deferred revenue, current portion

-

-

0

0

17

18

16

15

14

12

9

-

-

-

-

-

-

-

Short-term loan

-

-

-

-

-

-

-

-

-

-

-

-

2

-

-

-

-

-

Senior Promissory Note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

Warrants and Option liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2

Tax payable

19

13

9

2

6

5

1

1

9

9

2

3

2

0

0

0

0

-

Operating lease liabilities, current portion

14

10

10

9

9

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development cost share liability, current portion

128

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term bank loan

11

0

0

8

8

8

8

9

9

9

9

-

-

-

-

-

-

-

Total current liabilities

451

310

265

271

238

246

188

186

141

149

103

49

49

35

29

20

15

35

Non-current liabilities:
Long-term bank loan

81

83

104

84

77

40

40

51

9

9

9

17

17

17

18

10

6

6

Shareholder loan

157

157

150

154

155

148

146

149

154

146

140

135

-

-

-

-

-

-

Deferred revenue, non-current portion

-

-

0

0

8

-

14

18

21

24

29

-

-

-

-

-

-

-

Operating lease liabilities, non-current portion

32

25

18

18

19

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax liabilities

10

10

10

11

11

11

-

-

-

0

1

-

-

-

-

-

-

-

Research and development cost share liability, non-current portion

460

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rental

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Other long-term liabilities

45

46

36

38

38

48

34

21

22

31

0

1

0

0

0

0

0

0

Total non-current liabilities

788

323

321

307

310

249

236

240

208

212

181

153

18

17

18

10

6

7

Total liabilities

1,240

633

586

579

549

496

425

427

350

362

284

203

68

52

47

31

22

42

Commitments and contingencies

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

Convertible Preferred Shares / Total mezzanine equity - Series A (par value US$0.0001 per share; 120,000,000 shares authorized; 116,785,517 shares issued and outstanding as of December 31, 2015 and Series A-2 (par value US$0.0001 per share; 100,000,000 shares authorized; 83,205,124 shares issued and outstanding as of December 31, 2015)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

176

Equity:
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,007,976,816 and 801,340,698 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Additional paid-in capital

5,138

2,925

2,861

2,814

2,777

2,744

2,710

1,804

1,782

1,000

981

604

597

591

388

385

384

18

Accumulated other comprehensive loss

-6

-8

-14

-0

6

1

-0

3

0

-0

0

-0

-0

-0

-0

-1

-1

-1

Accumulated deficit

-2,319

-1,955

-1,567

-1,260

-1,174

-1,007

-738

-594

-438

-330

-231

-348

-288

-237

-199

-164

-140

-118

Total BeiGene, Ltd. shareholders’ equity

2,812

962

1,278

1,553

1,608

1,739

1,970

1,213

1,344

669

750

255

308

352

187

220

243

-101

Noncontrolling interest

14

16

15

17

13

14

12

13

14

14

14

14

-

-

-

-

-

-

Total equity

2,827

978

1,294

1,571

1,622

1,753

1,983

1,226

1,358

684

764

270

-

352

-

-

-

-

Total liabilities and equity

4,067

1,612

1,881

2,150

2,172

2,249

2,408

1,653

1,708

1,046

1,049

473

376

405

235

251

265

116